3
Green Day
1
$NRX Pharmaceuticals (NRXP.US)$
$Grove (GRVI.US)$
Day trade profit. thank you @The money makerfor recommendations
$Grove (GRVI.US)$
Day trade profit. thank you @The money makerfor recommendations
3
2
1
2
$Grove (GRVI.US)$
Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced the launch of Upexi, its wholly owned division to acquire promising Amazon and Ecommerce businesses.
Since 2020, funding has poured into Amazon aggregators, raising nearly $10 billion according to Marketplace Pulse. Investors are racing to fund these companies whose goals are to buy promising Amazon brands that buyers believe can be scaled. According to Marketplace Pulse, "The market had a breakout year in 2020 because of three factors: the pandemic accelerating spending on Amazon, Thrasio raising hundreds of millions of dollars, and Anker, an Amazon-native brand, going public." According to Bloomberg, Thrasio, having raised more than $2 billion, could see its IPO valued at more than $10 billion.
With the launch of Upexi, Grove intends to take direct aim at the Amazon Aggregation market. Grove plans to enter the market as a desirable suitor to which prospective business owners may sell. With Upexi, potential sellers will be able to access Grove's programmatic ad technology, in-house digital marketing experts, and direct partnership with a team of expert Amazon PPC buyers who fine tune listings or start from scratch.
Grove Inc. has made a name for itself in the CBD/cannabis space and has already begun expanding into other verticals. The company recently acquired Vitamedica, an online nutraceutical company, with a rapidly growing presence in ecommerce and Amazon. Through its in-house team of digital marketers, Grove is now pursuing more companies in health/wellness/beauty/pet care that they can take to the next level.
Grove's hemp business has fueled its growth up until this point, reporting 2021 fiscal year revenues, with key financial highlights:
$24.1 Million, a 250% Increase Over 2020
Net Earnings of $2.9 Million or $0.25 Per Share
4th Quarter revenues of $10.64 million a 361% growth over prior year quarter
Revenue guidance of $48-$55M for 2022
Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced the launch of Upexi, its wholly owned division to acquire promising Amazon and Ecommerce businesses.
Since 2020, funding has poured into Amazon aggregators, raising nearly $10 billion according to Marketplace Pulse. Investors are racing to fund these companies whose goals are to buy promising Amazon brands that buyers believe can be scaled. According to Marketplace Pulse, "The market had a breakout year in 2020 because of three factors: the pandemic accelerating spending on Amazon, Thrasio raising hundreds of millions of dollars, and Anker, an Amazon-native brand, going public." According to Bloomberg, Thrasio, having raised more than $2 billion, could see its IPO valued at more than $10 billion.
With the launch of Upexi, Grove intends to take direct aim at the Amazon Aggregation market. Grove plans to enter the market as a desirable suitor to which prospective business owners may sell. With Upexi, potential sellers will be able to access Grove's programmatic ad technology, in-house digital marketing experts, and direct partnership with a team of expert Amazon PPC buyers who fine tune listings or start from scratch.
Grove Inc. has made a name for itself in the CBD/cannabis space and has already begun expanding into other verticals. The company recently acquired Vitamedica, an online nutraceutical company, with a rapidly growing presence in ecommerce and Amazon. Through its in-house team of digital marketers, Grove is now pursuing more companies in health/wellness/beauty/pet care that they can take to the next level.
Grove's hemp business has fueled its growth up until this point, reporting 2021 fiscal year revenues, with key financial highlights:
$24.1 Million, a 250% Increase Over 2020
Net Earnings of $2.9 Million or $0.25 Per Share
4th Quarter revenues of $10.64 million a 361% growth over prior year quarter
Revenue guidance of $48-$55M for 2022
4
3
3
1
Glad that I sold at $17 yesterday before it dip . Thanks to @The money makerbuy and sell target
$DatChat (DATS.US)$
$DatChat (DATS.US)$
Yesterday posted on 4 potential stock.too bad did not buy WTRH and it hit at sell target $1.3. thank you @The money makerfor the source
$ESS Tech (GWH.US)$
$Biora Therapeutics (PROG.US)$
$Vinco Ventures (BBIG.US)$
$ESS Tech (GWH.US)$
$Biora Therapeutics (PROG.US)$
$Vinco Ventures (BBIG.US)$
4
5